A detailed history of Tower Research Capital LLC (Trc) transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 7,100 shares of IPSC stock, worth $7,455. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,100
Previous 17,032 58.31%
Holding current value
$7,455
Previous $43,000 72.09%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.44 - $3.29 $14,302 - $32,676
-9,932 Reduced 58.31%
7,100 $12,000
Q2 2024

Aug 13, 2024

BUY
$2.46 - $4.05 $31,182 - $51,337
12,676 Added 291.0%
17,032 $43,000
Q1 2024

May 15, 2024

BUY
$3.19 - $5.32 $1,295 - $2,159
406 Added 10.28%
4,356 $18,000
Q4 2023

Feb 13, 2024

SELL
$1.28 - $3.32 $30,593 - $79,351
-23,901 Reduced 85.82%
3,950 $13,000
Q3 2023

Nov 14, 2023

BUY
$2.0 - $3.23 $49,758 - $80,359
24,879 Added 837.11%
27,851 $55,000
Q2 2023

Aug 14, 2023

BUY
$2.91 - $3.53 $2,211 - $2,682
760 Added 34.36%
2,972 $9,000
Q1 2023

May 09, 2023

SELL
$3.4 - $5.11 $22,916 - $34,441
-6,740 Reduced 75.29%
2,212 $8,000
Q4 2022

Feb 10, 2023

BUY
$4.84 - $11.58 $23,207 - $55,526
4,795 Added 115.35%
8,952 $46,000
Q3 2022

Nov 10, 2022

BUY
$8.57 - $13.1 $7,747 - $11,842
904 Added 27.79%
4,157 $41,000
Q2 2022

Aug 15, 2022

BUY
$7.96 - $12.43 $19,573 - $30,565
2,459 Added 309.7%
3,253 $27,000
Q1 2022

May 12, 2022

SELL
$11.62 - $15.92 $26,389 - $36,154
-2,271 Reduced 74.09%
794 $10,000
Q4 2021

Feb 14, 2022

BUY
$13.93 - $23.62 $34,379 - $58,294
2,468 Added 413.4%
3,065 $49,000
Q3 2021

Nov 15, 2021

BUY
$20.8 - $31.93 $12,417 - $19,062
597 New
597 $15,000

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $61.8M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.